Brokers Offer Predictions for NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for NeuroPace in a report released on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.80) per share for the year, down from their prior estimate of ($0.79). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

A number of other research analysts also recently weighed in on NPCE. Wells Fargo & Company raised their price objective on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group initiated coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, NeuroPace presently has a consensus rating of “Moderate Buy” and an average target price of $14.80.

NeuroPace Price Performance

NASDAQ NPCE opened at $14.19 on Friday. The stock’s 50-day moving average is $11.75 and its two-hundred day moving average is $8.81. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.15. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter in the prior year, the business posted ($0.28) EPS.

Institutional Trading of NeuroPace

A number of hedge funds have recently modified their holdings of NPCE. Palumbo Wealth Management LLC acquired a new stake in shares of NeuroPace during the 4th quarter valued at about $129,000. JPMorgan Chase & Co. lifted its stake in NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after purchasing an additional 6,181 shares during the period. Financial Advocates Investment Management boosted its holdings in NeuroPace by 20.0% during the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares in the last quarter. Barclays PLC grew its stake in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the period. Finally, State Street Corp raised its holdings in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after buying an additional 12,912 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Insiders Place Their Bets

In related news, insider Martha Morrell sold 3,200 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares in the company, valued at $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 22.20% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.